HLA
OREX

Hamilton Lane Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Hamilton Lane Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,477
Closed -$86K – 72
2013
Q2 		$86K Buy
+1,477
New +$90.9K 0.05% 57

Other funds holding OREX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hamilton Lane Advisors's OREX Position: Q3 2013 in Review

Hamilton Lane Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2013, closing a stake of 1,477 shares — an estimated $86K sold.

Hamilton Lane Advisors first reported a position in OREX in Q2 2013 and held it in 1 quarter. The position peaked at $86K in Q2 2013. 130 funds tracked by Wall St. Rank hold OREX as of Q3 2013.

  • Hamilton Lane Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2013 after selling out during the quarter.
  • Hamilton Lane Advisors sold 1,477 Orexigen Therapeutics, Inc. shares in Q3 2013, an estimated $86K.
  • Hamilton Lane Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 1 quarter.
  • Hamilton Lane Advisors's Orexigen Therapeutics, Inc. position peaked at $86K in Q2 2013.
  • 130 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2013.

Based on Hamilton Lane Advisors's 13F filing for Q3 2013, filed 8 Oct 2013.